Vir Biotechnology (VIR) announced that Week 48 endpoint analysis from the Company’s Phase 2 SOLSTICE trial for chronic hepatitis delta, CHD, demonstrated that participants receiving a monthly dose of the combination of tobevibart and elebsiran achieved robust and sustained rates of hepatitis delta virus, HDV, RNA target not detected, TND, including those participants with cirrhosis and high baseline HDV RNA. The combination also showed alanine aminotransferase, ALT, reductions over time and a favorable safety profile. SOLSTICE trial data demonstrate that 66% of chronic hepatitis delta participants receiving a monthly dose of tobevibart and elebsiran achieved undetectable HDV RNA at Week 48
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VIR:
- Vir Biotechnology’s Earnings Call: Achievements and Challenges
- Positive Outlook for Vir Biotechnology: Buy Rating Driven by Promising Pipeline Developments and Strong Cash Position
- 3 Best Stocks to Buy Now, 11/6/2025, According to Top Analysts
- Vir Biotechnology’s Strategic Advancements in HDV and Oncology Programs Justify Buy Rating
- Vir Biotechnology: Strong Financials and Promising Clinical Developments Drive Buy Rating